Long-acting polypeptides and methods of producing same
A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
1. A method of extending C max of a cytokine comprising the step of attaching one chorionic gonadotropin carboxy terminal peptide (CTP) to the amino terminus of said cytokine and two chorionic gonadotropin carboxy terminal peptides to the carboxy terminus of said cytokine, thereby extending C max of said cytokine.
2. The method of claim 1 , wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18.
3. The method of claim 1 , wherein said at least one CTP is glycosylated.
4. The method of claim 1 , wherein said at least one CTP is truncated.
5. The method of claim 1 , wherein at least one CTP is optionally attached to said cytokine via a linker.
6. The method of claim 5 , wherein the linker is a peptide bond.
7. The method of claim 1 , wherein said attaching produces a CTP-modified cytokine polypeptide, wherein when said polypeptide is a precursor polypeptide said polypeptide consists of a cytokine attached to a single chorionic gonadotropin carboxy terminal peptide (CTP) at the amino terminus of said cytokine, and two chorionic gonadotropin carboxy terminal peptides (CTP) attached to the carboxy terminus of said cytokine, and a signal peptide attached to the amino terminus of said one CTP, and when said polypeptide is a mature polypeptide, said polypeptide consists of a cytokine attached to a single chorionic gonadotropin carboxy terminal peptide (CTP) at the amino terminus of said cytokine, and two chorionic gonadotropin carboxy terminal peptides (CTP) attached to the carboxy terminus of said cytokine and said polypeptide lacks a signal peptide.
8. A pharmaceutical composition comprising a buffer, a tonicity agent, and a polypeptide consisting of a cytokine attached to a single chorionic gonadotropin carboxy terminal peptide (CTP) at the amino terminus of said cytokine, and two chorionic gonadotropin carboxy terminal peptides (CTP) attached to the carboxy terminus of said cytokine.
9. The pharmaceutical composition of claim 8 , wherein said buffer is citrate.
10. The pharmaceutical composition of claim 8 , wherein said tonicity agent is NaCl.
11. The pharmaceutical composition of claim 8 , wherein said composition is at a pH of about 4-7.2.
12. The pharmaceutical composition of claim 8 , wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18.
13. The pharmaceutical composition of claim 8 , wherein said at least one CTP is glycosylated.
14. The pharmaceutical composition of claim 8 , wherein said at least one CTP is truncated.
15. The pharmaceutical composition of claim 8 , wherein at least one CTP is optionally attached to said cytokine via a linker.
16. The pharmaceutical composition of claim 15 , wherein the linker is a peptide bond.
17. The pharmaceutical composition of claim 8 , wherein when said polypeptide is a precursor polypeptide, said polypeptide consists of a cytokine attached to a single chorionic gonadotropin carboxy terminal peptide (CTP) at the amino terminus of said cytokine, and two chorionic gonadotropin carboxy terminal peptides (CTP) attached to the carboxy terminus of said cytokine, and a signal peptide attached to the amino terminus of said one CTP, and when said polypeptide is a mature polypeptide, said polypeptide consists of a cytokine attached to a single chorionic gonadotropin carboxy terminal peptide (CTP) at the amino terminus of said cytokine, and two chorionic gonadotropin carboxy terminal peptides (CTP) attached to the carboxy terminus of said cytokine and said polypeptide lacks a signal peptide.
18. The pharmaceutical composition of claim 8 , wherein said composition is a liquid.
19. The pharmaceutical composition of claim 8 , wherein said composition is administered once weekly or once bi-weekly.
20. The pharmaceutical composition of claim 8 , wherein said composition is formulated in a form suitable for an intramuscular (IM) injection, a subcutaneous (SC) injection, or an intravenous (IV) injection.